Literature DB >> 28984655

Mixed Versus Pure Variants of Desmoplastic Melanoma: The Cleveland Clinic Experience.

Ruzica Z Conic, Jennifer Ko, Sherihan H Allam, Natasha Atanaskova-Mesinkovska, Ivanka Kovalyshyn, Wilma Bergfeld, Brian R Gastman.   

Abstract

BACKGROUND: Desmoplastic melanoma (DM) is a subvariant of spindle cell melanoma, accounting for less than 4% of all cutaneous melanomas. It occurs later in life and is associated with chronic sun exposure. Desmoplastic melanoma prognosis is considered more favorable than other variants, with lower rates of metastasis and higher survival. Recently, DM has been further subclassified into pure and mixed, calling into question surgical management and patient outcomes as well as viability of current nationwide databases without this distinction.
METHODS: We identified all patients with a histopathologic diagnosis of DM from the Cleveland Clinic electronic melanoma database (n = 58) from 1997 to 2013. Clinical and histopathologic data were collected. Comparison in clinical variables was performed between patients who had pure (n = 15) and mixed (n = 43) variants of DM.
RESULTS: There were no differences in age, sex, location of lesion, Breslow depth, ulceration, or regression. Patients with mixed DM were more likely to have lymphovascular invasion (P = 0.03) compared with pure DM. There was no difference in performance of sentinel lymph node biopsy (P = 0.25) or sentinel lymph node positivity (P = 0.31) between the 2 groups. Recurrence was present in 13.3% of pure and 30.2% of mixed patients. Overall, Kaplan-Meier 3-year survival was 75% for pure and 80% for mixed DM (P = 0.53).
CONCLUSIONS: Pure and mixed DMs seem to have similar clinical characteristics and outcomes. This indicates that analysis of national datasets without this subclassification remains viable.

Entities:  

Mesh:

Year:  2018        PMID: 28984655      PMCID: PMC5801159          DOI: 10.1097/SAP.0000000000001225

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  17 in total

1.  Incidence and survival of desmoplastic melanoma in the United States, 1992-2007.

Authors:  Zhuang Feng; Xiaocheng Wu; Vivien Chen; Ellen Velie; Zhenzhen Zhang
Journal:  J Cutan Pathol       Date:  2011-04-26       Impact factor: 1.587

2.  Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.

Authors:  Noah Frydenlund; Dominick Leone; Shi Yang; Mai P Hoang; April Deng; Marier Hernandez-Perez; Rajendra Singh; Asok Biswas; Ron Yaar; Meera Mahalingam
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma.

Authors:  Timothy M Pawlik; Merrick I Ross; Victor G Prieto; Matthew T Ballo; Marcella M Johnson; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

4.  Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma).

Authors:  J Conley; R Lattes; W Orr
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

Review 5.  Is sentinel lymph node biopsy warranted for desmoplastic melanoma? A systematic review.

Authors:  Jonathan A Dunne; Justin C R Wormald; Jessica Steele; Elizabeth Woods; Joy Odili; Barry W E M Powell
Journal:  J Plast Reconstr Aesthet Surg       Date:  2016-11-16       Impact factor: 2.740

6.  The clinical behavior of desmoplastic melanoma.

Authors:  D E Jaroszewski; B A Pockaj; D J DiCaudo; U Bite
Journal:  Am J Surg       Date:  2001-12       Impact factor: 2.565

7.  Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma.

Authors:  Katherine E Posther; M Angelica Selim; Paul J Mosca; Wilma E Stanley; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg Oncol       Date:  2006-03-17       Impact factor: 5.344

8.  Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.

Authors:  Luis Soares de Almeida; Luis Requena; Arno Rütten; Heinz Kutzner; Claus Garbe; Dinis Pestana; Manuel Marques Gomes
Journal:  Am J Dermatopathol       Date:  2008-06       Impact factor: 1.533

Review 9.  Desmoplastic melanoma: a review.

Authors:  Lucy L Chen; Natalia Jaimes; Christopher A Barker; Klaus J Busam; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2012-12-23       Impact factor: 11.527

10.  Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

Authors:  Dale Han; Gang Han; Xiuhua Zhao; Nikhil G Rao; Jane L Messina; Suroosh S Marzban; Amod A Sarnaik; C Wayne Cruse; Vernon K Sondak; Jonathan S Zager
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

View more
  3 in total

1.  Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases.

Authors:  Sherman Chu; Kory P Schrom; Raghav Tripathi; Rosalynn R Z Conic; Harib H Ezaldein; Jeffrey F Scott; Kord Honda
Journal:  Am J Dermatopathol       Date:  2021-11-01       Impact factor: 1.319

2.  Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival.

Authors:  Annelien E Laeijendecker; Mary-Ann El Sharouni; Vigfús Sigurdsson; Paul J van Diest
Journal:  Cancer Med       Date:  2019-12-05       Impact factor: 4.452

3.  Evolving treatments and future therapeutic targets in desmoplastic melanoma.

Authors:  Matthew J Hadfield; Alla Turshudzhyan; Jane M Grant-Kels
Journal:  Melanoma Manag       Date:  2021-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.